Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.4491
-0.00600-1.32%
At close: -
$0.4554
0.006301.40%
After Hours: 5:28 PM EDT
Comments
Loading...
Adaptimmune Therapeutics Analyst Ratings and Price Targets | NASDAQ:ADAP | Benzinga
Adaptimmune Therapeutics PLC has a consensus price target of $3.86 based on the ratings of 10 analysts. The high is $10 issued by EF Hutton on August 10, 2023. The low is $1 issued by Barclays on August 10, 2023. The 3 most-recent analyst ratings were released by Mizuho, HC Wainwright & Co., and Guggenheim on November 27, 2024, November 19, 2024, and November 15, 2024, respectively. With an average price target of $2.67 between Mizuho, HC Wainwright & Co., and Guggenheim, there's an implied 485.57% upside for Adaptimmune Therapeutics PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
HC Wainwright & Co.
Guggenheim
Scotiabank
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Adaptimmune Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/27/2024 | Buy Now | 229.38% | Mizuho | Graig Suvannavejh55% | $3 → $1.5 | Maintains | Outperform | Get Alert |
| 11/19/2024 | Buy Now | 668.56% | HC Wainwright & Co. | Arthur He38% | $3.5 → $3.5 | Reiterates | Buy → Buy | Get Alert |
| 11/15/2024 | Buy Now | 558.76% | Guggenheim | Michael Schmidt57% | $4 → $3 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 668.56% | HC Wainwright & Co. | Arthur He38% | $4 → $3.5 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | 778.35% | HC Wainwright & Co. | Arthur He38% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 08/05/2024 | Buy Now | 778.35% | HC Wainwright & Co. | Arthur He38% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 07/30/2024 | Buy Now | 778.35% | HC Wainwright & Co. | Arthur He38% | → $4 | Initiates | → Buy | Get Alert |
| 05/30/2024 | Buy Now | 591.7% | Scotiabank | George Farmer48% | → $3.15 | Initiates | → Sector Outperform | Get Alert |
| 05/17/2024 | Buy Now | 558.76% | Mizuho | Graig Suvannavejh55% | $9 → $3 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 119.59% | Barclays | Peter Lawson42% | $2 → $1 | Maintains | Underweight | Get Alert |
| 06/05/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 05/26/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 03/06/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | $10 → $10 | Reiterates | → Buy | Get Alert |
| 01/05/2023 | Buy Now | 2095.87% | EF Hutton | Tony Butler43% | → $10 | Initiates | → Buy | Get Alert |
| 01/03/2023 | Buy Now | 997.94% | Guggenheim | Michael Schmidt57% | → $5 | Upgrade | Neutral → Buy | Get Alert |
| 11/14/2022 | Buy Now | 558.76% | Wells Fargo | Yanan Zhu34% | $1.5 → $3 | Maintains | Equal-Weight | Get Alert |
| 11/09/2022 | Buy Now | 1876.28% | Mizuho | Mara Goldstein56% | → $9 | Upgrade | Neutral → Buy | Get Alert |
| 10/04/2022 | Buy Now | 229.38% | Wells Fargo | Nick Abbott19% | $7 → $1.5 | Maintains | Equal-Weight | Get Alert |
| 05/09/2022 | Buy Now | 558.76% | SVB Leerink | Jonathan Chang39% | $2 → $3 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Adaptimmune Therapeutics (ADAP) stock?
The latest price target for Adaptimmune Therapeutics (NASDAQ:ADAP) was reported by Mizuho on November 27, 2024. The analyst firm set a price target for $1.50 expecting ADAP to rise to within 12 months (a possible 229.38% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptimmune Therapeutics (ADAP)?
The latest analyst rating for Adaptimmune Therapeutics (NASDAQ:ADAP) was provided by Mizuho, and Adaptimmune Therapeutics maintained their outperform rating.
When was the last upgrade for Adaptimmune Therapeutics (ADAP)?
The last upgrade for Adaptimmune Therapeutics PLC happened on January 3, 2023 when Guggenheim raised their price target to $5. Guggenheim previously had a neutral for Adaptimmune Therapeutics PLC.
When was the last downgrade for Adaptimmune Therapeutics (ADAP)?
There is no last downgrade for Adaptimmune Therapeutics.
When is the next analyst rating going to be posted or updated for Adaptimmune Therapeutics (ADAP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptimmune Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptimmune Therapeutics was filed on November 27, 2024 so you should expect the next rating to be made available sometime around November 27, 2025.
Is the Analyst Rating Adaptimmune Therapeutics (ADAP) correct?
While ratings are subjective and will change, the latest Adaptimmune Therapeutics (ADAP) rating was a maintained with a price target of $3.00 to $1.50. The current price Adaptimmune Therapeutics (ADAP) is trading at is $0.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.